Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment: An observational study in 38 016 patients in primary care

Clinical Drug Investigation

Volumn 24, Issue 4, 2004, Pages 217-225

  Lehnert, H ^a   Bramlage, P ^b   Pittrow, D ^b   Kirch, W ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; HYPERTENSION; HYPOKALEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 1842689678     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424040-00003     Document Type: Article

References (39)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
3. Ritz E. Albuminuria and vascular damage: the vicious twins. N Engl J Med 2003; 348: 2349-52
4. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25: 85-9
5. Hillege H, Janssen W, Bak A, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26
6. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6
7. Stehouwer C, Nauta J, Zeldenrust G, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23
8. Beatty O, Ritchie C, Bell P, et al. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes: an eight-year follow-up study. Diabet Med 1995; 12: 261-6
9. Damsgaard E, Froland A, Jorgensen O, et al. Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia 1993; 36: 1030-6
10. MacLeod J, Lutale J, Marshall S. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995; 38: 610-6
11. American Diabetes Association. Position statement on "diabetic nephropathy": position statement. Diabetes Care 2004; 27 Suppl. 1: S79-83
12. Hasslacher C. Diabetische Nephropathie in "Praxis-Leitlinien der Deutschen Diabetes Gesellschaft". Diabetes und Stoffwechsel 2002; 11 Suppl. 2: 179
13. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
16. Fernandez I, Paez Pinto J, Hermosin Bono T, et al. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetol 1998; 35: 199-202
17. Piehlmeier W, Renner R, Schramm W, et al. Screening of diabetic patients for microalbuminuria in primary care: The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes 1999; 107: 244-51
18. SAS. Cary NC: SAS Institute Inc., 1999
19. Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
20. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-72
21. Brueckel J, Koebberling J. Definition, Klassifikation und Diagnostik des Diabetes mellitus. In "Praxis-Leitlinien der Deutschen Diabetes Gesellschaft" Diabetes und Stoffwechsel 2002; 11 Suppl. 2: 6-8
22. Zelmanovitz T, Gross J, Oliveira J, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20: 516-9
23. Lum G. How effective are screening tests for microalbuminuria in random urine specimens? Ann Clin Lab Sci 2000; 30: 406-11
24. Vestbo E, Damsgaard E, Froland A, et al. Urinary albumin excretion in a population based cohort. Diabet Med 1995; 12: 488-93
25. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92
26. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
27. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-9
28. Taal M, Brenner B. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-17
29. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-31
30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
31. Myers MG. Compliance in hypertension: why don't patients take their pills? CMAJ 1999; 160: 64-5
32. Hasford J, Mimran A, Simons W. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75
33. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-65
34. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
35. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
36. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
37. Schulte K, Fischer M, Meyer-Sabellak W. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs: results of the AURA study. Clin Drug Invest 1999; 18: 453-60
38. Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000; 20: 1-7
39. Bramlage P, Wittchen H, Pittrow D, et al. Mikroalbuminurie als früher Marker für eine erhöhte Morbidität und Mortalität. Fortschr Med Orig 2003; 121 Suppl. I: 28-32